Enanta Pharmaceuticals, Inc. Share Price & Technical Analysis
ENTA · $13.53 (-3.01%)
Healthcare / Biotechnology
$13.53
-3.01%
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respirator…
Price chart
Seasonality
May has 0 positive and 3 negative years (last 5 years shown)
0% return in May, -14% avg return in past 3 year May month.
-8% return in 2026, -4% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -18% | 12% | -10% | 9% | 0% | – | – | – | – | – | – | – | -8% |
| 25 | -12% | 53% | -29% | 11% | 0% | 27% | 1% | 14% | 38% | 8% | 29% | 14% | 153% |
| 24 | 30% | 18% | 22% | -23% | -9% | 3% | 15% | -13% | -19% | 6% | -24% | -33% | -28% |
| 23 | 14% | -9% | -17% | -12% | -34% | -9% | -11% | -21% | -25% | -19% | 3% | 0% | -139% |
| 22 | -21% | 18% | 1% | -10% | -38% | 15% | 16% | 11% | -14% | -14% | -4% | 6% | -34% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Emerging · Neutral
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$400.47M
P/E ratio
—
52W high
$17.15
52W low
$5.70
Volume
3,04,806
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Enanta Pharmaceuticals, Inc. share price today?
- Enanta Pharmaceuticals, Inc. (ENTA) last traded around $13.53 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ENTA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ENTA. Download the app for real-time alerts.
- How can I analyze Enanta Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.